Table 3 Anti-AXL monoclonal antibodies and nucleotide aptamers currently being investigated
Name | Type | Target | Indications | Phase of clinical trials |
|---|---|---|---|---|
YW327.6S2 | Monoclonal antibody | AXL | NSCLC, breast cancer | Preclinical |
D9 | Monoclonal antibody | AXL | Pancreatic cancer | Preclinical |
E8 | Monoclonal antibody | AXL | Pancreatic cancer | Preclinical |
MAb173 | Monoclonal antibody | AXL | Kaposi sarcoma | Preclinical |
AXL-107-MMAE | Antibody-drug conjugate | AXL | Melanoma | Preclinical |
64Cu-anti-hAXL | 64Cu-labeled anti-human antibody | AXL | Breast cancer | Preclinical |
Axl specific CAR and SynNotch receptor | CAR and synNotch receptors | AXL | Leukemia | Preclinical |
GL21.T | RNA nucleotide aptamer | AXL | NSCLC | Preclinical |
GL21.T/miR-34c chimera | conjugate of miR-34c and GL21.T | AXL | NSCLC | Preclinical |
DNA AXL-APTAMER | DNA nucleotide aptamer | AXL | Ovarian cancer | Preclinical |